Novo Nordisk AS
NVO
Novo Nordisk AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
stocks
3 ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,712.80 | 44.30 | 0.51% |
| CAC 40 | 7,705.15 | 64.16 | -0.83% |
| DAX 40 | 22,295.58 | 317.39 | -1.40% |
| Dow JONES (US) | 45,603.48 | 356.63 | -0.78% |
| FTSE 100 | 9,954.80 | 17.37 | -0.17% |
| HKSE | 24,951.88 | 95.45 | 0.38% |
| NASDAQ | 21,146.28 | 261.80 | -1.22% |
| Nikkei 225 | 53,373.07 | 230.58 | -0.43% |
| NZX 50 Index | 12,935.39 | 41.60 | -0.32% |
| S&P 500 | 6,424.79 | 52.37 | -0.81% |
| S&P/ASX 200 | 8,516.30 | 44.70 | 0.53% |
| SSE Composite Index | 3,913.72 | 24.64 | 0.63% |